vis410
mAbexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2014 (NCT02045472)
Timeline
Indications
Mechanism of action
- HemagglutininINHIBITOR
HA inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- vis410
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03040141 | Phase 2 | Jun 1, 2017 | Visterra, Inc. |
| NCT02989194 | Phase 2 | Dec 1, 2016 | Department of Health and Human Services, Visterra, Inc. |
| NCT02468115 | Phase 2 | May 1, 2015 | SGS Life Sciences, Visterra, Inc. |
| NCT02045472 | Phase 1 | Sep 1, 2014 | Davita Clinical Research, Visterra, Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Visterra, Inc. | For profit | 4 | 4 | 2 | 2014 |
| Davita Clinical Research | For profit | 1 | 0 | 1 | 2014 |
| Department of Health and Human Services | Government | 1 | 0 | 1 | 2016 |
| SGS Life Sciences | For profit | 1 | 0 | 1 | 2015 |
4 organizations
Page 1 / 1